Z0063

Z0063 is an investigational antacid drug evaluated for its ability to increase gastric pH, thereby providing relief from conditions associated with excess stomach acid such as gastroesophageal reflux disease. In a Phase 1 clinical trial, its antacid activity and safety profile were compared to Gaviscon Double Action Tablets in healthy adult subjects. The study assessed the percentage of time intragastric pH remained at or above 4 over a four-hour period post-dose, as well as other pharmacodynamic and safety endpoints. The specific active ingredients and detailed mechanism of action for Z0063 have not been publicly disclosed.